Rezvilutamide
Small moleculeexperimental
Clinical trial activity
29 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
21
Phase 3
5
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02691975)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Drug Therapy · Phase 2
- Healthy Volunteers · Phase 1
- Liver Diseases · Phase 1
- Neoadjuvant Therapy · Phase 2
- Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Recurrence · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Androgen ReceptorANTAGONIST
Androgen Receptor antagonist
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1- Mol. weight
- 479.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650276 ↗
Also known as
- shr3680
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07241416 | Phase 3 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07230106 | Phase 2 | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT06832774 | Phase 2 | Apr 1, 2025 | Jiao Tong University |
| NCT06505278 | Phase 2 | Aug 31, 2024 | Sun Yat-Sen University |
| NCT06387056 | Phase 2 | Apr 1, 2024 | Xiamen University |
| NCT06348264 | Phase 2 | Mar 30, 2024 | Hengrui Therapeutics, Inc., Peking University |
| NCT06134271 | Phase 2 | Nov 15, 2023 | China Medical University |
| NCT07112209 | N/A | Nov 6, 2023 | Southern Medical University |
| NCT06305832 | Phase 2 | Sep 7, 2023 | Nanjing University |
| NCT05983783 | Phase 3 | Aug 1, 2023 | Nanjing Medical University |
| NCT05928780 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2023 | Fudan University |
| NCT05956639 | Phase 3 | Jun 20, 2023 | Nanjing Medical University |
| NCT05753566 | Phase 2 | Mar 31, 2023 | Hengrui Therapeutics, Inc., Nanjing University |
| NCT05607693 | Phase 1 | Dec 5, 2022 | Hengrui Therapeutics, Inc. |
| NCT05009290 | Phase 3 | Sep 1, 2021 | Hengrui Therapeutics, Inc. |
| NCT04903158 | Phase 1 | Jan 6, 2021 | Hengrui Therapeutics, Inc. |
| NCT04631549 | Phase 1 | Dec 31, 2020 | Hengrui Therapeutics, Inc. |
| NCT04621669 | Phase 1 | Nov 19, 2020 | Hengrui Therapeutics, Inc. |
| NCT04603833 | Phase 2 | Oct 30, 2020 | Hengrui Therapeutics, Inc. |
| NCT04676035 | Phase 1 | Jun 1, 2020 | Hengrui Therapeutics, Inc. |
Showing 20 of 29 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 16 | 14 | 3 | 2016 |
| Fudan University | Academic/Hospital | 6 | 3 | 2 | 2016 |
| Nanjing University | Academic/Hospital | 3 | 3 | 1 | 2020 |
| Nanjing Medical University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Xiamen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
12 organizations
Page 1 / 1